Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2015

View Archived Issues

RNA vaccine iHIVARNA-01 enters phase I trial in patients with HIV-1 infection

AbbVie presents key events from second quarter 2015

Heptares and Regeneron enter StaR protein collaboration

DNDi and Takeda collaborate on aminopyrazole series for visceral leishmaniasis

Cross-talk between Ret and Parkin has a key role in dopaminergic neuron survival

Catabasis Pharmaceuticals sponsors research into SREBP pathway involvement in lipid disorders

Boehringer Ingelheim signs license agreement with Hanmi for HM-61713

Oncolys BioPharma and Kagoshima University to jointly search for novel anti-HBV agents

Merck & Co. to acquire CEACAM-1 targeting immunotherapy developer cCAM Biotherapeutics

Bristol-Myers Squibb introduces ROR-gamma modulators

Pfizer reflects on key milestones of second quarter 2015

Qu Biologics begins phase II trial of QBECO SSI for ulcerative colitis

Inovio Pharmaceuticals begins trial of INO-5150 for prostate cancer

Patient-derived antibody is active against Middle East Respiratory Syndrome

A*STAR discloses MNK inhibitors

Novartis introduces PTP-2C inhibitors

Aurigene presents BET protein inhibitors

CIMA patents antifibrinolytics

Arena Pharmaceuticals begins phase II trial of APD-334

FDA clears IND for RXDX-107

Osteoprotegerin levels indicative of aortic valvular stenosis

New start-up Mereo BioPharma acquires programs from Novartis

Kyowa Hakko Kirin and BMS to study combination of mogamulizumab and nivolumab

Navidea receives NIH grants to study Manocept in atherosclerosis and rheumatoid arthritis

Astellas reports topline data from ACTIVE study of isavuconazole

FDA clears KaloBios' IND for KB-003 for chronic myelomonocytic leukemia

FDA accepts NDA for ZS-9 in hyperkalemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...